公开(公告)号：US12234298B2

公开(公告)日：2025-02-25

申请号：US17238787

申请日：2021-04-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  A61M5/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  G01N33/574 ,  C07K7/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11890333B2

公开(公告)日：2024-02-06

申请号：US17390583

申请日：2021-07-30

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61P35/00 ,  A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/705 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/6886

CPC classification number: A61K39/0011 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70539 ,  C07K16/2833 ,  C12Q1/6886 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/80 ,  C07K2319/33 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11648276B2

公开(公告)日：2023-05-16

申请号：US16891841

申请日：2020-06-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: C07K7/06 ,  C07K14/47 ,  C07K14/495 ,  C07K14/725 ,  A61K35/17 ,  C07K7/08 ,  A61K39/00 ,  C07K16/40 ,  C07K19/00 ,  C12N9/02 ,  C12N9/10 ,  C12N5/0783 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/495 ,  C07K14/7051 ,  C07K16/40 ,  C07K19/00 ,  C12N5/0638 ,  C12N9/0036 ,  C12N9/13 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/34 ,  C07K2319/00 ,  C12N2502/1157 ,  C12Y208/02011

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10047124B2

公开(公告)日：2018-08-14

申请号：US15226206

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10047123B2

公开(公告)日：2018-08-14

申请号：US15226002

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US11529401B2

公开(公告)日：2022-12-20

申请号：US17852207

申请日：2022-06-28

Applicant: Immatics Biotechnologies GmbH

Inventor： Sabrina Kuttruff-Coqui ,  Toni Weinschenk ,  Jens Fritsche ,  Steffen Walter ,  Norbert Hilf ,  Oliver Schoor ,  Colette Song ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61P35/00 ,  A61K35/17 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/705 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/6886

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10941181B2

公开(公告)日：2021-03-09

申请号：US15226161

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K38/00 ,  C07K7/06 ,  A61K39/00 ,  C07K7/08 ,  A61K35/17 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10709735B2

公开(公告)日：2020-07-14

申请号：US16507437

申请日：2019-07-10

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/495 ,  C07K14/725 ,  C07K19/00 ,  C12N5/0783 ,  C07K7/06 ,  C07K7/08 ,  C07K16/40 ,  C12N9/02 ,  C12N9/10 ,  A61K38/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10420800B2

公开(公告)日：2019-09-24

申请号：US16196402

申请日：2018-11-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/495 ,  C12N9/02 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K19/00 ,  C07K14/725 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/10 ,  A61K38/00

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US10046037B2

公开(公告)日：2018-08-14

申请号：US15226081

申请日：2016-08-02

Applicant: immatics biotechnologies GmbH

Inventor： Toni Weinschenk ,  Oliver Schoor ,  Claudia Trautwein ,  Norbert Hilf ,  Steffen Walter ,  Harpreet Singh

IPC: A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  G01N33/574 ,  C07K14/74 ,  A61M5/00 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/6081 ,  A61K2039/6093 ,  A61M5/002 ,  C07K7/08 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0638 ,  C12N2501/50 ,  G01N33/57492 ,  Y02A50/472

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.